• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用

潘佳佳, 贾晓青, 黄岗, 张玉彬

潘佳佳, 贾晓青, 黄岗, 张玉彬. PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用[J]. 中国药科大学学报, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102
引用本文: 潘佳佳, 贾晓青, 黄岗, 张玉彬. PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用[J]. 中国药科大学学报, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102
shu
PAN Jiajia, JIA Xiaoqing, HUANG Gang, ZHANG Yubin. PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102
Citation: PAN Jiajia, JIA Xiaoqing, HUANG Gang, ZHANG Yubin. PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(1): 9-18. DOI: 10.11665/j.issn.1000-5048.20160102
shu

PD-1/PD-Ls信号通路及其抗体在肿瘤治疗中的应用

  • 中国药科大学生命科学与技术学院

PD-1/PD-Ls signaling pathway and the application of anti-PD-1/PD-Ls antibodies in cancer therapy

摘要

    摘要
  • 摘要: 程序性死亡受体-1(PD-1)是T细胞上主要存在的一种抑制性受体，与其配体PD-L1、PD-L2相互作用，可抑制T细胞增殖、活化和细胞因子的分泌。在正常机体中，PD-1/PD-Ls信号通路对维持机体的免疫耐受具有重要作用；而在肿瘤发生时，PD-1/PD-Ls信号通路能抑制T细胞的免疫反应而促进肿瘤免疫逃逸的发生。本文从PD-1/PD-Ls的结构与表达、信号通路的作用机制、PD-1/PD-L1的可溶性分子(sPD-1/sPD-L1)的表达特性及其对PD-1/PD-Ls途径的作用等方面简述了PD-1/PD-Ls信号通路的研究现状，综述了抗PD-1/PD-Ls抗体及其在肿瘤免疫治疗中的临床应用。
    Abstract: Programmed death-1(PD-1)is a major co-suppression receptor expressed on T cells. Binding with its ligands(PD-L1 and PD-L2), PD-1 can inhibit T cell proliferation, activation and cytokine secretion. In normal organs, PD-1/PD-Ls signaling pathway plays an important role in maintaining immune tolerance, while suppressing T cell immune response and promoting tumor immune escape during tumorigenesis. This article reviews the research progress on PD-1/PD-Ls signaling pathway from the structure and expression of PD-1/PD-Ls, the mechanism of the signaling pathway as well as the expression characteristics of soluble form of PD-1/PD-L1(sPD-1/sPD-L1), and summarizes the categories of anti-PD-1/ PD-Ls antibodies and their clinical trials in cancer immunotherapy.
    • HTML全文
    • 参考文献(50)
  • [1] Hamid O,Carvajal RD.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy[J].Expert Opin Biol Ther,2013,13(6):847-861.
    [2] Saudemont A,Quesnel B.In a model of tumor dormancy,long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis[J].Blood,2004,104(7):2124-2133.
    [3] Zhang L,Gajewski TF,Kline J.PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model[J].Blood,2009,114(8):1545-1552.
    [4] Dai S,Jia R,Zhang X,et al.The PD-1/PD-Ls pathway and autoimmune diseases[J].Cell Immunol,2014,290(1):72-79.
    [5] López-Medina M,Carrillo-Martín I,Leyva-Rangel J,et al.Salmonella impairs CD8 T cell response through PD-1:PD-L axis[J].Immunobiology,2015,220(12):1369-1380.
    [6] La X,Zhang F,Li Y,et al.Upregulation of PD-1 on CD4+CD25+T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis[J].Int Immunopharmacol,2015,26(2):357-366.
    [7] Li T,Ma R,Zhu JY,et al.PD-1/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance[J].Transplant Proc,2015,47(1):165-170.
    [8] Ohaegbulam KC,Assal A,Lazar-Molnar E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.
    [9] Swaika A,Hammond WA,Joseph RW.Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J].Mol Immunol,2015,6(7):4-17.
    [10] Sunshine J,Taube JM.PD-1/PD-L1 inhibitors[J].Curr Opin Pharmacol,2015,23: 32-38.
    [11] Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation,but only receptor ligation prevents T cell activation[J].J Immunol,2004,173(2):945-954.
    [12] Thompson RH,Dong H,Lohse CM,et al.PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma[J].Clin Cancer Res,2007,13(6):1757-1761.
    [13] Zhang Y,Huang S,Gong D,et al.Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+;T lymphocytes in human non-small cell lung cancer[J].Cell Mol Immunol,2010,7(5):389-395.
    [14] Kleffel S,Posch C,Barthel SR,et al.Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth[J].Cell,2015,162(6):1242-1256.
    [15] Messal N,Serriari NE,Pastor S,et al.PD-L2 is expressed on activated human T cells and regulates their function[J].Mol Immunol,2011,48(15):2214-2219.
    [16] Lesterhuis WJ, Steer H, Lake RA. PD-L2 is predominantly expressed by Th2 cells[J].Mol Immunol,2011,49(1):1-3.
    [17] Ghiotto M,Gauthier L,Serriari N,et al.PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1[J].Int Immunol,2010,22(8):651-660.
    [18] Chapoval AI,Ni J,Lau JS,et al.B7-H3:a costimulatory molecule for T cell activation and IFN-gamma production[J].Nat Immunol,2001,2(3):269-274.
    [19] Chikuma S,Terawaki S,Hayashi T,et al.PD-1-mediated suppression of IL-2 production induces CD8+T cell anergy in vivo[J].J Immunol,2009,182(11):6682-6689.
    [20] Bishop KD,Harris JE,Mordes JP,et al.Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+)T lymphocytes via an interleukin-2-dependent mechanism[J].Cell Immunol,2009,256(1/2):86-91.
    [21] Wang S,Bajorath J,Flies DB,et al.Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction[J].J Exp Med,2003,197(9):1083-1091.
    [22] Elhag O A,Hu XJ,Wen-Ying Z,et al.Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity[J].Asian Pac J Cancer Prev,2012,13(8):4031-4036.
    [23] Song MY, Park SH, Nam HJ, et al. Enhancement of vaccine-induced primary and memory CD8(+)T-cell responses by soluble PD-1[J].J Immunother,2011,34(3):297-306.
    [24] Kuipers H,Muskens F,Willart M,et al.Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+T cell activation[J].Eur J Immunol,2006,36(9):2472-2482.
    [25] Wan B,Nie H,Liu A,et al.Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis[J].J Immunol,2006,177(12):8844-8850.
    [26] Frigola X,Inman B A,Krco CJ,et al.Soluble B7-H1:differences in production between dendritic cells and T cells[J].Immunol Lett,2012,142(1):78-82.
    [27] Frigola X,Inman BA,Lohse CM,et al.Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma[J].Clin Cancer Res,2011,17(7):1915-1923.
    [28] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.
    [29] Topalian SL,Sznol M,McDermott DF,et al.Survival,durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab[J].J Clin Oncol,2014,32(10):1020-1030.
    [30] Robert C,Long GV,Brady B,et al.Nivolumab in previously untreated melanoma without BRAF mutation[J].N Engl J Med,2015,372(4):320-330.
    [31] Weber JS,D′Angelo SP,Minor D,et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment(CheckMate 037):a randomised,controlled,open-label,phase 3 trial[J].Lancet Oncol,2015,16(4):375-384.
    [32] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
    [33] Motzer RJ,Rini BI,McDermott D F,et al.Nivolumab for metastatic renal cell carcinoma:results of a randomized phase II trial[J].J Clin Oncol,2015,33(13):1430-1437.
    [34] Ansell SM,Lesokhin AM,Borrello I,et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin′s lymphoma[J].N Engl J Med,2015,372(4):311-319.
    [35] Hamid O,Robert C,Daud A,et al.Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma[J].N Engl J Med,2013,369(2):134-144.
    [36] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521-2532.
    [37] Moskowitz CH,Ribrag V,Michot JM,et al.PD-1 blockade with the monoclonal antibody pembrolizumab(MK-3475)in patients with classical Hodgkin lymphoma after brentuximab vedotin failure:preliminary results from a phase 1b study(KEYNOTE-013)[J].Blood,2014,124(21):290.
    [38] Seiwert TY,Burtness B,Weiss J,et al.A phase Ib study of MK-3475 in patients with human papillomavirus(HPV)-associated and non-HPV-associated head and neck(H/N)cancer[C]//ASCO Annual Meeting Proceedings,2014,32(15 Suppl):6011.
    [39] Atkins MB,Kudchadkar RR,Sznol M,et al.Phase 2,multicenter,safety and efficacy study of pidilizumab in patients with metastatic melanoma[C]//ASCO Annual Meeting Proceedings,2014,32(15 Suppl):9001.
    [40] Westin JR,Chu F,Zhang M,et al.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group,open-label,phase 2 trial[J].Lancet Oncol,2014,15(1):69-77.
    [41] Mkrtichyan M,Najjar YG,Raulfs EC,et al.B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets[J].J Immunol,2012,189(5):2338-2347.
    [42] Powles T,Eder JP,Fine GD,et al.MPDL3280A(anti-PD-L1)treatment leads to clinical activity in metastatic bladder cancer[J].Nature,2014,515(7528):558-562.
    [43] Herbst RS,Gordon MS,Fine GD,et al.A study of MPDL3280A,an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors[C]//ASCO Annual Meeting Proceedings,2013,31(15 Suppl):3000.
    [44] Emens LA,Braiteh FS,Cassier P,et al.Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer(TNBC)[J].Cancer Res,2015,75(15 Suppl):2859-2859.
    [45] Ibrahim R,Stewart R,Shalabi A.PD-L1 blockade for cancer treatment:MEDI4736[J].Semin Oncol,2015,42(3):474-483.
    [46] Segal NH,Antonia SJ,Brahmer JR,et al.Preliminary data from a multi-arm expansion study of MEDI4736,an anti-PD-L1 antibody[J].J Clin Oncol,2014,32(15 suppl):134136-134144.
    [47] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455-2465.
    [48] Disis ML,Patel MR,Pant S,et al.Avelumab(MSB0010718C),an anti-PD-L1 antibody,in patients with previously treated,recurrent or refractory ovarian cancer:a phase Ib,open-label expansion trial[C]//ASCO Annual Meeting Proceedings,2015,33(15 Suppl):5509.
    [49] McDermott DF,Atkins MB.PD-1 as a potential target in cancer therapy[J].Cancer Med,2013,2(5):662-673.
    [50] Teixido C,Karachaliou N,Gonzalez-Cao M,et al.Assays for predicting and monitoring responses to lung cancer immunotherapy[J].Cancer Biol Med,2015,12(2):87-95.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-02-24

目录

摘要
HTML全文
    参考文献(50)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：400372

    x 关闭 永久关闭